AOD-9604: the fat loss fragment — what it does and what the research shows

AOD-9604 (Anti-Obesity Drug 9604) was developed by Monash University and Metabolic Pharmaceuticals in Australia during the 1990s as a targeted anti-obesity compound. It is the C-terminal fragment of HGH (amino acids 176–191), with a tyrosine added at the N-terminus to improve stability and bioavailability. The peptide completed Phase I, II, and III clinical trials. It was not approved as a commercial drug due to insufficient cardiovascular outcome data in Phase III, but it remains available via 503A compounding pharmacy prescription in the US under physician supervision.

HGH has two functionally distinct domains. The N-terminal region drives growth promotion and IGF-1 stimulation. The C-terminal region (which AOD-9604 is derived from) regulates fat metabolism. AOD-9604 activates beta-3 adrenergic receptors in adipocytes, stimulating hormone-sensitive lipase and triggering triglyceride hydrolysis (lipolysis). Simultaneously, it inhibits lipogenesis — the synthesis of new fat from dietary carbohydrates. Critically, it does not bind IGF-1 receptors and does not stimulate IGF-1 production. This specificity is the key clinical advantage over full HGH.

Phase II dose-finding (n=300): compared 0.25mg, 0.5mg, and 1.0mg per day vs placebo. The 0.5mg dose showed the optimal efficacy-to-side-effect profile. Phase III (n=536, 24 weeks): 0.5mg/day AOD-9604 produced significant reduction in body fat percentage vs placebo. The primary effect is adipose tissue remodeling — particularly visceral and subcutaneous truncal fat. Total scale weight loss was modest (1.5–2.5kg) because the mechanism targets fat tissue specifically, and lean mass is maintained or slightly improved. Adverse event rates were similar to placebo across all dose groups.

Full synthetic HGH at 2–4 IU/day produces fat loss plus lean mass gain, but also elevates IGF-1, impairs glucose tolerance, and increases carpal tunnel and edema risk with chronic use. Monthly cost: $500–$1,500. AOD-9604 delivers targeted fat metabolism without IGF-1 elevation, without glucose effects, without anabolic side effects. Monthly cost: $80–$200. For patients whose goal is purely body fat reduction — not muscle building — AOD-9604 has a more favorable risk-to-benefit profile than full HGH.

Standard dose: 250–500mcg subcutaneous injection per day. Morning administration on an empty stomach is preferred — insulin's counter-regulatory effect on beta-adrenergic receptors reduces AOD-9604 efficacy when blood glucose is elevated. No food for 30 minutes after injection. Frequency schedule: 5 days on, 2 days off — consistent with the receptor management approach used in other peptide protocols. Cycle duration: 12–24 weeks, followed by an 8-week break. Body composition measurement (DEXA or InBody) at baseline and 12 weeks to quantify fat mass changes.

With CJC-1295/Ipamorelin: the body recomposition stack — secretagogues promote lean mass while AOD-9604 reduces fat. This is the most common multi-peptide combination for adults seeking composition changes without anabolic steroids or full HGH. With semaglutide or tirzepatide: GLP-1 produces caloric restriction; AOD-9604 specifically targets the adipose tissue. No pharmacokinetic interaction documented, but blood glucose monitoring is prudent given overlapping metabolic effects. With resistance training: body composition changes are substantially more pronounced when combined with 3+ sessions of progressive resistance training per week.

AOD-9604 is most appropriate for: patients who have plateaued on diet and exercise, targeting stubborn visceral or truncal fat deposits that are resistant to caloric restriction, GLP-1 patients seeking enhanced adipose tissue reduction without increasing GLP-1 dose, and patients who want HGH-like fat loss effects without the IGF-1 elevation concern. It is not appropriate for: active malignancy (any agent affecting adipose tissue metabolism warrants caution), pregnancy or breastfeeding, children and adolescents, or patients with uncontrolled diabetes.

Physician consultation, body composition baseline, and PCAB-accredited compounding pharmacy. Prescriptions issued for individual patients with clinical indication.

Frequently Asked Questions